5 337

Cited 8 times in

Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer

DC FieldValueLanguage
dc.contributor.author김은영-
dc.contributor.author김주항-
dc.contributor.author김한상-
dc.contributor.author김혜련-
dc.contributor.author박무석-
dc.contributor.author박지수-
dc.contributor.author이준호-
dc.contributor.author임선민-
dc.contributor.author임승택-
dc.contributor.author장준-
dc.contributor.author정지예-
dc.contributor.author김건민-
dc.contributor.author조병철-
dc.contributor.author김다래-
dc.contributor.author김세규-
dc.contributor.author김세현-
dc.contributor.author김영삼-
dc.date.accessioned2014-12-18T09:00:20Z-
dc.date.available2014-12-18T09:00:20Z-
dc.date.issued2013-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/87356-
dc.description.abstractThe aim of this study was to investigate the efficacy and safety of belotecan in combination with cisplatin in patients with previously non-treated extensive stage small cell lung cancer. A total of 42 patients were enrolled and treated with combination of belotecan 0.5 mg/m2 on daily basis throughout day 1–4 and cisplatin 60 mg/m2 on day 1 of a 3-week cycle, up to 6 cycles. Treatment was continued until the completion of 6 cycles of the chemotherapy, disease progression, detection of unacceptable toxicity, withdrawal of the consent, or death of the patient. Response was assessed every 2 cycles of chemotherapy by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Toxicity was assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0. The overall response rate was 73.8% in an intention to treat population and 83.9% in the evaluable patients. With the median follow up of 9.9 months, the median progression free survival was 6.9 months (95% CI, 6.6–7.2 months), and median overall survival was 11.2 months (95% CI, 9.9–12.5 months). The frequently reported grade ≥ 3 toxicities were neutropenia (90.2%), thrombocytopenia (63.4%), and anemia (34.1%). Febrile neutropenia was reported in 16 patients (39.0%). Although most of non-hematologic toxicities were grade 1 or 2, there were 4 patient deaths caused by pneumonia complicated by septic shock. Belotecan and cisplatin combination chemotherapy demonstrated a promising efficacy in ED SCLC patients. But, the hematologic toxicity of this regimen requires considerable amount of attention.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHCamptothecin/administration & dosage-
dc.subject.MESHCamptothecin/adverse effects-
dc.subject.MESHCamptothecin/analogs & derivatives*-
dc.subject.MESHCisplatin/administration & dosage*-
dc.subject.MESHCisplatin/adverse effects-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDrug-Related Side Effects and Adverse Reactions-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHNeoplasm Metastasis/drug therapy*-
dc.subject.MESHNeoplasm Metastasis/pathology-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHSmall Cell Lung Carcinoma/drug therapy*-
dc.subject.MESHSmall Cell Lung Carcinoma/pathology-
dc.subject.MESHYoung Adult-
dc.titlePhase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSeungtaek Lim-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorJi Ye Jung-
dc.contributor.googleauthorGun Min Kim-
dc.contributor.googleauthorSe Hyun Kim-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorHan Sang Kim-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorJi Soo Park-
dc.contributor.googleauthorJun Ho Lee-
dc.contributor.googleauthorDarae Kim-
dc.contributor.googleauthorEun Young Kim-
dc.contributor.googleauthorMoo Suk Park-
dc.contributor.googleauthorYoung Sam Kim-
dc.contributor.googleauthorSe Kyu Kim-
dc.contributor.googleauthorJoon Chang-
dc.contributor.googleauthorJoo Hang Kim-
dc.identifier.doi10.1016/j.lungcan.2013.02.009-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00945-
dc.contributor.localIdA01166-
dc.contributor.localIdA01457-
dc.contributor.localIdA01686-
dc.contributor.localIdA03181-
dc.contributor.localIdA03369-
dc.contributor.localIdA03380-
dc.contributor.localIdA03472-
dc.contributor.localIdA03735-
dc.contributor.localIdA00287-
dc.contributor.localIdA03822-
dc.contributor.localIdA00361-
dc.contributor.localIdA00602-
dc.contributor.localIdA00607-
dc.contributor.localIdA00707-
dc.contributor.localIdA00811-
dc.contributor.localIdA01098-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid23510628-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500213000688-
dc.subject.keywordExtensive disease-
dc.subject.keywordSmall cell lung cancer-
dc.subject.keywordChemotherapy-
dc.subject.keywordBelotecan-
dc.subject.keywordCisplatin-
dc.subject.keywordResponse-
dc.contributor.alternativeNameKim, Eun Young-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameKim, Han Sang-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNamePark, Moo Suk-
dc.contributor.alternativeNamePark, Ji Soo-
dc.contributor.alternativeNameLee, Jun Ho-
dc.contributor.alternativeNameLim, Sun Min-
dc.contributor.alternativeNameLim, Seung Taek-
dc.contributor.alternativeNameChang, Joon-
dc.contributor.alternativeNameJung, Ji Ye-
dc.contributor.alternativeNameKim, Gun Min-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameKim, Da Rae-
dc.contributor.alternativeNameKim, Se Kyu-
dc.contributor.alternativeNameKim, Se Hyun-
dc.contributor.alternativeNameKim, Young Sam-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.contributor.affiliatedAuthorPark, Moo Suk-
dc.contributor.affiliatedAuthorPark, Ji Soo-
dc.contributor.affiliatedAuthorLee, Jun Ho-
dc.contributor.affiliatedAuthorLim, Sun Min-
dc.contributor.affiliatedAuthorLim, Seung Taek-
dc.contributor.affiliatedAuthorChang, Joon-
dc.contributor.affiliatedAuthorJung, Ji Ye-
dc.contributor.affiliatedAuthorKim, Gun Min-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorKim, Da Rae-
dc.contributor.affiliatedAuthorKim, Se Kyu-
dc.contributor.affiliatedAuthorKim, Se Hyun-
dc.contributor.affiliatedAuthorKim, Young Sam-
dc.contributor.affiliatedAuthorKim, Eun Young-
dc.contributor.affiliatedAuthorKim, Han Sang-
dc.rights.accessRightsnot free-
dc.citation.volume80-
dc.citation.number3-
dc.citation.startPage313-
dc.citation.endPage318-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.80(3) : 313-318, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.